FBIOP
Fortress Biotech, Inc.
Set alert
- YTD
- +59.11%
- 1 year
- +120.12%
- Open
- 15.39
- Prev close
- 15.59
- Mkt cap
- 35.16M
- Vol
- 24.34K
- Avg vol
- 12.22K
- EPS
- -0.863
- P/E
- 0.00
- Div yield
- 45.96%
More statistics
- Low
- 15.05
- High
- 15.76
- Forward P/E
- 0.00
- Beta
- 1.75
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 2.34
- Ex-div date
- Jun 13, 2024
- 50-d avg
- 5.83
- 200-d avg
- 10.33
- 1y target
- 0.00
Key statistics
- Market cap
- 35.16M
- Enterprise value
- 96.10M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.43
- Price / book
- 4.39
- EPS (TTM)
- -0.863
- Beta
- 1.75
- Dividend yield
- 45.96%
- Payout ratio
- 0.00%
- Profit margin
- -49.25%
- Revenue (TTM)
- 82.62M
- Revenue growth
- -14.30%
- Free cash flow
- -59.20M
- Total cash
- 76.20M
- Total debt
- 88.42M
- Return on equity
- 0.00%
- Shares outstanding
- 56.68M
- Short % of float
- 0.00%
- 50-day average
- 5.83
- 200-day average
- 10.33
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About Fortress Biotech, Inc.
Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- fortressbiotech.com
News
- Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
- Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
- Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
- Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
- Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
- Fortress Biotech (NASDAQ:FBIOP) Stock Price Up 22.9% – Here’s What Happened
- 12 Health Care Stocks Moving In Monday's Intraday Session
- UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Your note
Sign in to keep a note on FBIOP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| JIN DAVID | Chief Financial Officer | Purchase | Jul 9, 2024 | 500 |
| ROSENWALD LINDSAY A | Chief Executive Officer | Purchase | Jul 10, 2024 | 127,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Shikiar Asset Management, Inc. | 0.44% | 15,000 | 98.25K | Jun 29, 2023 |